Waters Corp.

WAT ·Technology, Scientific & Technical Instruments, United States

Waters Corporation (WAT)

Overview

Waters Corporation is a global life sciences, diagnostics, and materials science company headquartered in Milford, Massachusetts. Founded in 1958, it built its franchise as a specialist in analytical instrumentation, most notably liquid chromatography and mass spectrometry systems used to identify and measure the chemical composition of substances. The company was transformed on February 9, 2026, when it completed a landmark $17.5 billion merger with the Biosciences & Diagnostic Solutions business of Becton, Dickinson and Company (BD), roughly doubling its scale. Post-merger, Waters employs on the order of 16,000 people worldwide and is guiding to full-year 2026 revenue of approximately $6.4–$6.5 billion, up from roughly $3.2 billion as a standalone company in 2025.

What They Do & How They Make Money

Waters makes money selling scientific instruments, the consumables and chemistries those instruments run on, and the software and services that support them — a classic "razor and blades" model common in life-science tools. Customers are pharmaceutical and biotech companies, contract research and manufacturing organizations, food and environmental testing labs, clinical and public-health laboratories, materials and battery manufacturers, and academic and government research institutions. A lab buys a chromatography or mass spectrometry system (the capital "razor"), then continues to purchase proprietary columns, reagents, and chemistries (the recurring "blades") for years afterward, along with service contracts, software licenses (such as its Empower chromatography data software), and periodic instrument upgrades. This produces a durable, high-margin recurring revenue stream layered on top of cyclical capital-equipment sales. With the BD Biosciences & Diagnostic Solutions integration, Waters has added flow cytometry, single-cell biology, and regulated clinical/point-of-care diagnostic testing products, extending the same instrument-plus-consumables economics into biology and diagnostics rather than only chemistry and materials analysis.

Business Segments

Following the BD combination, Waters reorganized into four operating divisions:

Waters Analytical Sciences — the legacy core of the company: liquid chromatography (e.g., ACQUITY UPLC), mass spectrometry (Xevo series), and related detection technologies, plus compliant informatics, serving pharma quality control, food safety, and environmental testing. This remains the largest and most profitable division (~$607M revenue in Q1 2026, high-single-digit instrument growth, mid-teens chemistry growth).
Waters Biosciences — flow cytometry, cellular sorting, and single-cell analysis tools acquired from BD, serving immunology and cell-biology research (~$232M in Q1 2026, newly reported post-acquisition).
Waters Advanced Diagnostics — regulated, high-volume clinical diagnostic workflows including microbiology, molecular diagnostics, and point-of-care testing, also acquired from BD (~$349M in Q1 2026).
Waters Materials Sciences — thermal analysis, rheometry, and calorimetry instruments (the former "TA" division) used to characterize batteries, polymers, electronics materials, and pharmaceutical formulations (~$79M in Q1 2026, mid-single-digit growth).

Prior to the merger, Waters reported simply through two divisions, Waters and TA (Thermal Analysis); the four-division structure reflects the newly combined, more diversified life-sciences-and-diagnostics portfolio.

Competitors

Analytical Sciences (chromatography/mass spec): Agilent Technologies, Thermo Fisher Scientific, Shimadzu, and Danaher (via SCIEX)
Biosciences (flow cytometry/cell analysis): Becton Dickinson's remaining businesses, Thermo Fisher, Danaher (Beckman Coulter, Cytiva), and Sony Biotechnology
Advanced Diagnostics: Roche Diagnostics, Abbott, bioMérieux, Danaher (Cepheid), and Hologic
Materials Sciences: TA Instruments' historical rivals include Malvern Panalytical (Spectris), Netzsch, and Anton Paar

Revvity and Danaher are frequently cited as broad life-science-tools competitors across multiple Waters segments.

Competitive Position

Waters has long held a leading position in liquid chromatography, an entrenched, mission-critical technology in pharmaceutical quality control and regulatory-compliance testing, where switching costs are high because methods are validated and locked into regulatory filings. This creates a durable, sticky installed base and high-margin consumables/service annuity. The BD Biosciences & Diagnostic Solutions merger materially broadens the company's addressable market into flow cytometry, single-cell biology, and regulated clinical diagnostics — areas with structurally higher growth and recurring testing volumes than instrument-heavy legacy chromatography, while diversifying revenue away from cyclical pharma and biotech capital spending. Early integration commentary points to revenue synergies and the acquired businesses outperforming guidance, suggesting the combination is off to a strong start. Key risks include: integration execution risk given the scale of combining two large organizations; substantial acquisition-related debt; continued softness or volatility in pharma/biotech instrument capital spending (a cyclical headwind that has weighed on the sector); competitive and pricing pressure from larger, better-capitalized rivals like Thermo Fisher and Danaher; exposure to academic/government funding cycles (e.g., NIH budgets); and regulatory/reimbursement risk in the newly acquired diagnostics business. Longer term, the combined "Waters Analytical Sciences, Biosciences, Advanced Diagnostics, and Materials Sciences" portfolio positions the company as a more complete life-sciences-and-diagnostics platform, but realizing the promised synergies and cross-selling opportunities will be the key test of the deal's value creation.